Gastroenterology Deal Benchmarks
IBD, Crohn's, celiac, NASH, and GI disease deal benchmarks. Benchmarks derived from 49 verified transactions.
49
Total Deals
$540M
Avg Upfront
4
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
23
license
17
acquisition
8
collaboration
1
option
0
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
GSK → Alfasigma linerixibat | license | $300M | $690M | Mar 2026 |
GSK → Alfasigma linerixibat | license | $300M | — | Mar 2026 |
Beam Therapeutics → Pfizer | option | $300M | $1.4B | Mar 2026 |
Theriva Biologics → Rasayana Therapeutics SYN-020 | license | $0M | $36M | Feb 2026 |
Ribo Life Science → Madrigal Pharmaceuticals siRNA MASH portfolio | license | $60M | $4.4B | Jan 2025 |
Ochre Bio → Boehringer Ingelheim Ochre RNA program | collaboration | $35M | $1.3B | Sep 2024 |
Morphic Holding → Eli Lilly MORF-057 | acquisition | $3.2B | $3.2B | Jul 2024 |
Teva Pharmaceutical → Sanofi ulcerativeColitis | license | $500M | $2.0B | Jul 2024 |
Phathom Pharmaceuticals → Alfasigma gerd | acquisition | $450M | $450M | Jul 2024 |
Celsius Therapeutics → AbbVie ibd | acquisition | $250M | $250M | Jul 2024 |
Benchmark Your Gastroenterology Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 49 verified gastroenterology transactions.
Run Gastroenterology Benchmark